NRD
HCAT icon

Nebula Research & Development’s Health Catalyst HCAT Stock Holding History

Nebula Research & Development’s Portfolio HCAT Stock Details HCAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-25,305
Closed -$95.4K – 391
2025
Q2 		$95.4K Sell
25,305
-19,405
-43% -$76.3K 0.01% 924
2025
Q1 		$203K Sell
44,710
-3,863
-8% -$20.4K 0.02% 862
2024
Q4 		$343K Sell
48,573
-7,428
-13% -$59.2K 0.04% 678
2024
Q3 		$456K Buy
56,001
+19,963
+55% +$144K 0.05% 579
2024
Q2 		$230K Buy
36,038
+24,625
+216% +$158K 0.04% 689
2024
Q1 		$85.9K Sell
11,413
-30,673
-73% -$280K 0.02% 694
2023
Q4 		$390K Buy
+42,086
New +$344K 0.12% 332

Other funds holding HCAT

FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WCA
Whetstone Capital Advisors Shawnee Mission, Kansas $288M AUM 44.06% 1-Year Est. Return
Impax Asset Management Group
Impax Asset Management Group London, United Kingdom $14.3B AUM 19.8% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
NI
Nepsis Inc Minneapolis, Minnesota $295M AUM 35.44% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Nebula Research & Development's HCAT Position: Q3 2025 in Review

Nebula Research & Development sold out of Health Catalyst (HCAT) in Q3 2025, closing a stake of 25,305 shares — an estimated $95.4K sold.

Nebula Research & Development first reported a position in HCAT in Q4 2023 and held it in 7 quarters. The position peaked at $456K in Q3 2024. 145 funds tracked by Wall St. Rank hold HCAT as of Q3 2025.

  • Nebula Research & Development reported no remaining Health Catalyst position as of Q3 2025 after selling out during the quarter.
  • Nebula Research & Development sold 25,305 Health Catalyst shares in Q3 2025, an estimated $95.4K.
  • Nebula Research & Development first reported a position in Health Catalyst in Q4 2023 and held it in 7 quarters.
  • Nebula Research & Development's Health Catalyst position peaked at $456K in Q3 2024.
  • 145 funds tracked by Wall St. Rank held Health Catalyst as of Q3 2025.

Based on Nebula Research & Development's 13F filing for Q3 2025.